1
|
Zhang W, Cai S, Luan W, Ding M, Di L. Integrated serum pharmacochemistry, network pharmacology and experimental verification to explore the mechanism of Aconiti Lateralis Radix Praeparata in treatment of lung cancer. J Pharm Biomed Anal 2025; 252:116472. [PMID: 39278160 DOI: 10.1016/j.jpba.2024.116472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2024] [Revised: 09/08/2024] [Accepted: 09/11/2024] [Indexed: 09/17/2024]
Abstract
Aconiti Lateralis Radix Praeparata (Fuzi) is a traditional Chinese medicine (TCM) widely used in treating cancer. Our formerly investigations confirmed the anti-lung cancer efficacy of Fuzi, but systematic analysis of the ingredients of Fuzi absorbed into serum and the corresponding molecular mechanism in treating lung cancer remained unknown. In this work, UPLC-Q-TOF-MS was applied to detect the ingredients of Fuzi in rat serum. Next, the possible targets and key pathways of the components absorbed into serum of Fuzi were predicted by network pharmacology. Then, the binding activity of components and potential targets were performed by molecular docking. Afterwards, the proliferation, mitochondrial membrane potential (MMP), apoptosis and reactive oxygen species (ROS) of lung cancer cells after treatment with Fuzi-containing serum were determined by MTT assay, JC-1 fluorescent probe, Annexin V-FITC/PI double staining and DCFH-DA respectively. Finally, the predicted target was further validated with qRT-PCR. In total, identification of 20 components of Fuzi derived from rat serum were achieved. The prediction of network pharmacology indicated that these compounds might exert their therapeutic effects by modulating mTOR. The findings from molecular docking proved that fuziline, songorine, napelline and hypaconitine exhibited binding potential with the mTOR. Cancer cell experiments revealed that the Fuzi-containing serum inhibited cell proliferation, induced apoptosis, reduced MMP and increased ROS. Additionally, Fuzi-containing serum significantly reduced the mRNA expression of mTOR. This study revealed that fuziline, songorine, napelline and hypaconitine were the main ingredients of Fuzi absorbed into serum. Furthermore, Fuzi-containing serum demonstrated inhibitory effects on the proliferation of lung cancer cells and induced the apoptosis. Combined with the results of network pharmacology, molecular docking and biological verification, Fuzi-containing serum might exert its anti-lung cancer effect by inhibiting mTOR. This study would provide a deeper understanding of Fuzi in treating lung cancer and offer a scientific reference for its clinical utilization.
Collapse
Affiliation(s)
- Wen Zhang
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine, Nanjing 210023, China.
| | - Shuhui Cai
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine, Nanjing 210023, China
| | - Wenhao Luan
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine, Nanjing 210023, China
| | - Menglei Ding
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine, Nanjing 210023, China; Department of Pharmacy, Kunshan Hospital of Chinese Medicine, Suzhou China
| | - Liuqing Di
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine, Nanjing 210023, China.
| |
Collapse
|
2
|
Huang L, Ma B, Zhang C, Shi J, Shen R, Zhang E, Lian C, Wang C, Liu J. Unveiling poly(rC)-binding protein 2 as the target protein for curcusone C against prostate cancer: mechanism validation through click chemistry-activity based proteomics profiling approach. BMC Cancer 2023; 23:957. [PMID: 37814239 PMCID: PMC10563230 DOI: 10.1186/s12885-023-11467-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 10/01/2023] [Indexed: 10/11/2023] Open
Abstract
BACKGROUND Prostate cancer is a disease that seriously troubles men. However, there are some inevitable limitations in interventional therapy for prostate cancer patients at present, most of which are caused by low selectivity and high toxic side effects due to unclear drug targets. In this study, we identified the target protein of Curcusone C with anti-prostate cancer potential activity and verified its target and mechanism of action. METHODS Click chemistry-activity based proteomics profiling (CC-ABPP) method was used to find target protein of Curcusone C against prostate cancer. Competitive CC-ABPP, drug affinity responsive target stability (DARTS) and surface plasmon resonance (SPR) methods were used to verifying the target protein. Moreover, potential mechanism was validated by western blot in vitro and by hematoxylin-eosin (HE) staining, detection of apoptosis in tumor tissue (TUNEL), and immunohistochemical (IHC) in vivo. RESULTS We found that poly(rC)-binding protein 2 (PCBP2) was the target protein of Curcusone C. In addition, Curcusone C might disrupt the Bax/Bcl-2 balance in PC-3 cells by inhibiting the expression of the target protein PCBP2, thereby inducing mitochondrial damage and activation of the mitochondrial apoptosis pathway, and ultimately inducing apoptosis of prostate cancer cells. CONCLUSIONS Curcusone C is a potential compound with anti-prostate cancer activity, and this effect occurs by targeting the PCBP2 protein, which in turn may affect the TGF/Smad signaling pathway and Bax/Bcl-2 balance. Our results laid a material and theoretical foundation for Curcusone C, to be widely used in anti-prostate cancer.
Collapse
Affiliation(s)
- Lan Huang
- School of medicine, Huaqiao University, Quanzhou, 362021, China
| | - Buqing Ma
- School of medicine, Huaqiao University, Quanzhou, 362021, China
| | - Chong Zhang
- School of medicine, Huaqiao University, Quanzhou, 362021, China
| | - Jiaqi Shi
- School of medicine, Huaqiao University, Quanzhou, 362021, China
| | - Rui Shen
- School of medicine, Huaqiao University, Quanzhou, 362021, China
| | - Erci Zhang
- School of medicine, Huaqiao University, Quanzhou, 362021, China
| | - Chenlei Lian
- School of medicine, Huaqiao University, Quanzhou, 362021, China
| | - Cuifang Wang
- Quanzhou Normal University, Quanzhou, 362000, China.
| | - Jieqing Liu
- School of medicine, Huaqiao University, Quanzhou, 362021, China.
| |
Collapse
|
3
|
Huang S, Lv Y, Wang JZ, Ye MZ, Lu RJ, Chen L, Xie J, Gao F, Zhou XL. Metabolite Profiling of Talatisamine in Heart Tissue After Oral Administration and Analysis of Cardiac Bioactivities. PLANTA MEDICA 2023; 89:674-682. [PMID: 36202094 DOI: 10.1055/a-1956-7542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The lateral roots of the Aconitum carmichaelii ("Fuzi") have been used for centuries as a cardiotonic in China. The diterpenoid alkaloid talatisamine (TA) is a major bioactive component of Fuzi, but the identity and bioactivities of the TA metabolites have not been examined in detail. In this study, metabolite profiling of TA was performed in rat heart by UPLC-MS following oral administration. Metabolites were identified by comparing protonated molecules, fragmentation patterns, and chromatographic behaviors with those of standard compounds. Metabolites of TA were then prepared and tested for cardiotonic activity on isolated frog hearts. The metabolite cammaconine, a C19 diterpenoid alkaloid with a hydroxyl group at C-18, exhibited substantial cardiotonic activity during frog heart perfusion. To further investigate the structure-cardiac effect relationships, a series of C19-diterpenoid alkaloids with 18-OH were prepared. Eight tested compounds (5: -12: ) demonstrated measurable cardioactivity, of which compound 5: with an N-methyl group and compound 7: with a methoxy at C-16 showed stronger effects on ventricular contraction than the other compounds. Thus, 18-OH is a critical structural feature determining cardiotonic activity, and efficacy is improved by the presence of N-methyl or methoxy at C-16. Preliminary mechanistic studies suggested that the cardiotonic effect of compound 5: is mediated by enhanced cellular calcium influx. Metabolites of TA with these structural features may be useful therapeutics to prevent heart failure.
Collapse
Affiliation(s)
- Shuai Huang
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, P. R. China
- Yibin Institute of Southwest Jiaotong University, Yibin, Sichuan, P. R. China
| | - Yang Lv
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, P. R. China
| | - Jian-Zhu Wang
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, P. R. China
| | - Mei-Zhen Ye
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, P. R. China
| | - Rui-Jie Lu
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, P. R. China
| | - Lin Chen
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, P. R. China
| | - Jiang Xie
- The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, P. R. China
| | - Feng Gao
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, P. R. China
| | - Xian-Li Zhou
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, P. R. China
- The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, P. R. China
| |
Collapse
|
4
|
Hosseinpour Z, Zamanian Azodi M, Jahani Sherafat S, Rezaei Tavirani M. Targeting colon cancer via antimicrobial RT2 peptide: a system biology study. GASTROENTEROLOGY AND HEPATOLOGY FROM BED TO BENCH 2023; 16:415-420. [PMID: 38313359 PMCID: PMC10835091 DOI: 10.22037/ghfbb.v16i4.2695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Accepted: 07/25/2023] [Indexed: 02/06/2024]
Abstract
Aim This study aims to investigate the anticancer molecular mechanism of RT2 through protein-protein interaction (PPI) network analysis. For this aim, a bioinformatics evaluation of the proteome profile of colon cancer is carried out. Background Antimicrobial peptides such as RT2 showed anticancer properties against various tumors. The molecular mechanism of the anticancer effect of RT2 is a challenging subject. Methods By applying Cytoscape V.3.9.1 and integrated apps, the profile of the interaction network and related centrality is analyzed. An enrichment analysis of hub bottlenecks was also performed, and highlighted biological processes were visualized and determined. Results Several 207 differentially expressed proteins were retrieved by PPI network analysis, and 10 hub bottlenecks were introduced. Among these differentially expressed proteins (DEPs), only AKT1 is from the queried DEPs. Key biological processes contributing to RT2 targeting mechanism include "Regulation of fibroblast proliferation", "Positive regulation of cyclin-dependent protein serine/threonine kinase activity", "positive regulation of miRNA transcription", and "fungiform papilla formation". Conclusion In conclusion, central proteins Tp53, MYC, EGFR, AKT1, HDAC1, and SRC can be introduced as a targeted biomarker panel of bioactive peptide treatments. However, extensive research is required to establish this claim before clinical application.
Collapse
Affiliation(s)
- Zahra Hosseinpour
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mona Zamanian Azodi
- Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Somayeh Jahani Sherafat
- Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mostafa Rezaei Tavirani
- Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|